| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/15/2004 | WO2004005291A1 Hetero-cyclicaly substituted imidazotriazines |
| 01/15/2004 | WO2004005290A1 Substituted imidazotriazines |
| 01/15/2004 | WO2004005285A1 New quinuclidine amide derivatives |
| 01/15/2004 | WO2004005276A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives |
| 01/15/2004 | WO2004005258A1 Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| 01/15/2004 | WO2004005257A1 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof |
| 01/15/2004 | WO2004005256A2 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors |
| 01/15/2004 | WO2004005255A1 N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors |
| 01/15/2004 | WO2004005243A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives |
| 01/15/2004 | WO2004004778A1 Use of cetp inhibitors and optionally hmg coa reductable inhibitors and/or antihypertensive agents |
| 01/15/2004 | WO2004004776A1 Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004736A1 Novel use of imidazotriazinones |
| 01/15/2004 | WO2004004733A1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo[2,1-b]-quinazolinone derivatives |
| 01/15/2004 | WO2004004729A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases |
| 01/15/2004 | WO2004004726A1 Mchir antagonists |
| 01/15/2004 | WO2004004724A1 Novel pharmaceutical compositions comprising novel anticholinergic agents and nk1-receptor antagonists |
| 01/15/2004 | WO2004004722A1 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(nk-1) antagonists for the treatment of emesis, depression, anxiety and cough |
| 01/15/2004 | WO2004004721A1 Use of ssri inhibitors to prevent or ameliorate trauma-related psychological disorders |
| 01/15/2004 | WO2004004699A2 Use of dantrolene, a ryanodine antagonist, in treating neural injury |
| 01/15/2004 | WO2004004698A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | WO2004004695A1 Extended-release tablets comprising divalproex sodium |
| 01/15/2004 | WO2004004656A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | WO2004004653A2 Methods for treating psychosis associated with interferon-alpha therapy |
| 01/15/2004 | WO2004004648A2 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use |
| 01/15/2004 | WO2004004641A2 PKC ACTIVATION AS A MEANS FOR ENHANCING sAPPα SECRETION AND IMPROVING COGNITION USING BRYOSTATIN TYPE COMPOUNDS |
| 01/15/2004 | WO2004004638A2 Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects |
| 01/15/2004 | WO2004004633A2 Use of tnfalpha antibodies and another drug |
| 01/15/2004 | WO2004004451A1 Methods of screening compounds for grk6 modulating activity |
| 01/15/2004 | WO2003094831A3 Novel diazabicyclic biaryl derivatives |
| 01/15/2004 | WO2003092608A3 Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| 01/15/2004 | WO2003091247A3 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| 01/15/2004 | WO2003089434A3 IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES METHOD OF MAKING AND METHOD OF USE THEREOF |
| 01/15/2004 | WO2003084936A8 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| 01/15/2004 | WO2003082216A3 Neuroprotectant methods, compositions, and screening methods thereof |
| 01/15/2004 | WO2003082191A3 Substituted 2,3-diphenyl pyridines |
| 01/15/2004 | WO2003080118A3 Combination of an aldosterone receptor antagonist and a fibric acid derivative |
| 01/15/2004 | WO2003079969A3 Compositions and methods for treating and preventing necrosis |
| 01/15/2004 | WO2003070895A3 RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/15/2004 | WO2003062191A8 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 01/15/2004 | WO2003057170A8 Oral insulin therapy |
| 01/15/2004 | WO2003057148A3 Use of biomolecular targets in the treatment and visualization of tumors |
| 01/15/2004 | WO2003055992A3 A method for the establishment of a pluripotent human blastocyst-derived stem cell line |
| 01/15/2004 | WO2003019146A3 High throughput screening assays using fatty acid synthetic enzymes |
| 01/15/2004 | WO2003016467A3 Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass |
| 01/15/2004 | WO2002096866A3 Thiolalkyl benzoic acid derivatives |
| 01/15/2004 | WO2002080966A8 Method for producing a vaccine containing autologous antibodies |
| 01/15/2004 | US20040010148 Antiinflammatory agents, antiallergens, antiproliferative agents, immunosuppressants, antidiabetic agents, cardiovascular disorders |
| 01/15/2004 | US20040010146 Process for the preparation imidazo[1,2-A]pyridine-3-acetamides |
| 01/15/2004 | US20040010142 Potassium channel moderators; antidiabetic agents |
| 01/15/2004 | US20040010141 Antiinflammatory agents; anticancer agents; rheumatic disorders; cardiovascular disorders |
| 01/15/2004 | US20040010134 Albumin fusion proteins |
| 01/15/2004 | US20040010027 Tumor angiogenesis and metastasis inhibition. |
| 01/15/2004 | US20040010022 2-aminooxazole derivatives |
| 01/15/2004 | US20040010021 Administering famotidine or its therapeutically acceptable salts |
| 01/15/2004 | US20040010020 Trifluoromethyl-substituted nitrogen compounds; treating type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumors, and glaucoma |
| 01/15/2004 | US20040010019 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 01/15/2004 | US20040010014 Novel compounds as opioid receptor modulators |
| 01/15/2004 | US20040010013 Cannabinoid receptor ligands |
| 01/15/2004 | US20040010011 Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same |
| 01/15/2004 | US20040010010 Melanocortin receptor ligands |
| 01/15/2004 | US20040010008 Piperidine derivatives useful as CCR5 antagonists |
| 01/15/2004 | US20040010007 Also thio, sulfoxy and sulfonyl derivatives; imidazotetrazolopyrimidines and intermediates |
| 01/15/2004 | US20040010000 Methods and dosage forms for controlled delivery of oxycodone |
| 01/15/2004 | US20040009998 Spiro-hydantoin compounds useful as anti-inflammatory agents |
| 01/15/2004 | US20040009996 4-(1,2- or 2,1-benzoxazol-5-yl)-2-aminopyrimidines |
| 01/15/2004 | US20040009995 Treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade |
| 01/15/2004 | US20040009994 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 01/15/2004 | US20040009991 Calcium channel antagonistic activity; especially useful as analgesics |
| 01/15/2004 | US20040009984 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure |
| 01/15/2004 | US20040009983 Azaindoles |
| 01/15/2004 | US20040009979 Use of compounds for the elevation of pyruvate dehydrogenase activity |
| 01/15/2004 | US20040009970 5HT2c agonists or partial agonists; e.g., 4,5,6,7,9a,10,11,12,13,13a-decahydro-9H-(1,4)diazepino-(6,7,1 -de)phenanthridine hydrochloride |
| 01/15/2004 | US20040009968 Indazole compounds useful as protein kinase inhibitors |
| 01/15/2004 | US20040009965 Treating hyperproliferative disorders |
| 01/15/2004 | US20040009950 Secreted human proteins |
| 01/15/2004 | US20040009926 Geriatric depression is treated with L-carnitine or an alkanoyl L-carnitine or salt, preferably acetyl L-carnitine thereby avoiding unwanted side-effects exhibited by conventional antidepressant agents. |
| 01/15/2004 | US20040009922 A PKC V5 isozyme-specific peptide, or a modification, derivation, fragment, combination, or hybrid thereof |
| 01/15/2004 | US20040009912 Method for treating schizoprhenia and related phychoes, and the use of erythropoietin or erythropoietin derivatives for treating schizophrenic disorders and related pyschoes |
| 01/15/2004 | US20040009905 Templates consist of cyclized peptides containing at least two residues in said cyclized peptide are joined by a naphthyl ring; and having bonded to it a linear peptide |
| 01/15/2004 | US20040009901 Identifying and administering an agent that enhances NADPH oxidase activity; diagnosing an autoimmune condition accompanied by NADPH oxidase deficiency |
| 01/15/2004 | US20040009897 Stabilized synthetic immunogen delivery system |
| 01/15/2004 | US20040009595 Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
| 01/15/2004 | US20040009593 Differentiated cell population which generate glial cells for treating central nervous system traumas and disorders |
| 01/15/2004 | US20040009505 A pair of genetic engineered primers for the mutagenic amplification, therapeutic treatment |
| 01/15/2004 | US20040009244 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 01/15/2004 | US20040009216 Administering liposomes comprising phospholipids and an aqueous layer, said liposomes having specified average diameter; treating various cardiovascular disorders, reducing cholesterol |
| 01/15/2004 | US20040009180 Transdermal botulinum toxin compositions |
| 01/15/2004 | US20040009169 Administration of agents for the treatment of inflammation |
| 01/15/2004 | US20040009167 Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain; use in preventing or treating a pathogen infection in a cell or organism |
| 01/15/2004 | DE10229070A1 Phenylderivate 5 Phenyl derivatives 5 |
| 01/15/2004 | DE10226326A1 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene 9-alpha-substiuierte estratrienes as selective estrogens effective |
| 01/15/2004 | CA2492535A1 New quinuclidine amide derivatives |
| 01/15/2004 | CA2492122A1 Novel tricyclic spiropiperidines or spiropyrrolidines |
| 01/15/2004 | CA2492010A1 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | CA2491921A1 Hetero-cyclically substituted imidazotriazines |
| 01/15/2004 | CA2491848A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 01/15/2004 | CA2491835A1 Mch1r antagonists |
| 01/15/2004 | CA2491689A1 Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof |
| 01/15/2004 | CA2491500A1 Substituted imidazotriazines |